Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences